Several clinical trials are ongoing to test MK-2206 monotherapy or in combination with targeted therapy or chemotherapy for metastatic breast cancer and in combination with lapatinib and trastuzumab for HER2-positive breast cancer (NCT01277757, NCT01245205, and NCT01235897). This evidence concerns the gene ERBB2 and breast carcinoma.